COMPANY

Genelux

HQ: Westlake Village, CA source · genelux.com ↗ · West Coast

Keywords: oncology solid tumor tumors Fallopian Tube Cancer Peritoneal Carcinomatosis Platinum-resistant Ovarian Cancer Platinum-refractory Ovarian Cancer Primary Peritoneal Cancer High-grade Serous Ovarian Cancer Endometrioid Ovarian Cancer Ovarian Clear Cell Carcinoma Ovarian Cancer Advanced Non-squamous Non-small-cell Lung Cancer Advanced Squamous Non-Small Cell Lung Carcinoma Metastatic Non-squamous Non Small Cell Lung Cancer Metastatic Squamous Non-Small Cell Lung Carcinoma Non-small Cell Lung Cancer Non-small Cell Lung Cancer Stage III Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer Recurrent Acute Myeloid Leukemia Cancer of Head and Neck GL-ONC1

Location: Westlake Village, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$30.5MRaised (2 yrs)7Trials (company is sponsor)

Timeline

Jan 8, 2026 Raise Follow-on offering: $20M (total, as published), announced Jan 8, 2026. Source: SEC filing. source ↗
Mar 25, 2025 Raise Follow-on offering: $10.5M (total, as published), announced Mar 25, 2025. Source: SEC filing. source ↗
Sep 26, 2024 Trial start Phase 2: Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer source ↗
Aug 31, 2022 Trial start Phase 3: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrim source ↗
2016-05 Trial start Phase 1/Phase 2: Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer source ↗
2012-04 Trial start Phase 1: Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer source ↗
2012-02 Trial start Phase 1/Phase 2: A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis source ↗
2008-11 Trial start Phase 1: Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Phase 3 · Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-30 · NCT05281471
2027-02 (ESTIMATED) · Phase 2 · Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer · NCT06463665

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $30.5M. Last 2 years.

Jan 8, 2026 Follow-on offering: $20M (total, as published), announced Jan 8, 2026. Source: SEC filing. source ↗
Mar 25, 2025 Follow-on offering: $10.5M (total, as published), announced Mar 25, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT05281471	Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)	Phase 3	Recruiting	Aug 31, 2022	2026-12 (estimated)
NCT02759588	Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer	Phase 1/Phase 2	Completed	2016-05	Dec 31, 2021 (actual)
NCT06463665	Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer	Phase 2	Recruiting	Sep 26, 2024	2027-02 (estimated)
NCT01443260	A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis	Phase 1/Phase 2	Completed	2012-02	2014-09 (actual)
NCT00794131	Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors	Phase 1	Completed	2008-11	2015-11 (actual)
NCT03420430	Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care	Not listed	No longer available	Not listed	Not listed
NCT01584284	Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer	Phase 1	Completed	2012-04	2015-06 (actual)